A little green might not be a cure for the blues. New research suggests medical marijuana isn’t the mental health miracle ...

The largest review of medicinal cannabis to date found it doesn’t effectively treat anxiety, depression, or PTSD—despite millions using it for those reasons. Researchers warn it could even make mental ...

In 2026, R&D speed is about learning faster, scaling responsibly and reducing risk in an increasingly complex system, says ...

Skincare tourism is growing as aesthetic treatments rise. SkinCeuticals enters Hainan with proven products like Advanced RGN-6, placing clinical skincare at the point of treatment.

There’s a very insightful formulation on page 65 of the brilliant historian Luke Kemp’s indispensable book Goliath’s Curse: The History and Future of ...

CHANGGE CITY, HENAN PROVINCE, CHINA, March 20, 2026 /EINPresswire.com/ -- The abrasive disc is one of the most widely ...

Beta-cyclodextrin remains the most widely produced and commercially used form, largely because of its favorable cavity size, relatively low production cost, and well-documented safety profile.

Fast-tracked psychedelics hit a wall: why the FDA’s pause on psilocybin is an important check to ensure safety, rigor, and ...

Viatris (VTRS) targets 5–6% revenue and 9–10% EPS CAGR through 2030, backed by launches, pipeline and $11B M&A cash. Click here to read my most recent analysis.

The use of the agricultural input glyphosate may be one of the most hotly contested issues within public health right now.

NASA's Artemis II mission is sending humans back to the moon for the first time since the Apollo era. Here are the reasons ...

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2025 Earnings Call Transcript March 19, 2026 Relmada Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.27 EPS, expectations were ...